Search Results - "Khatkova, E. I."

Potential of primary drug prevention of cardiotoxicity in the context of anticancer therapy by Vasyuk, Yu. A., Shupenina, E. Y., Novosel, E. O., Vyzhigin, D. A., Nosova, A. G., Zhukova, L. G., Filonenko, D. A., Khatkova, E. I.

“…Aim . To search early signs of cardiotoxicity in patients receiving anticancer therapy and evaluate the effectiveness of cardioprotection with an…”
Get full text

Olaparib in the metastatic HER2-negative breast cancer setting by Zhukova, L. G., Khatkova, E. I., Ganshina, I. P., Kolyadina, I. V., Lubennikova, E. V.

“…Understanding of cancer biology is at the cornerstone of design of new and effective treatment strategies. Identification of molecular drivers of tumor growth…”
Get full text

Target therapy of luminal HER2-negative advanced breast cancer with PIK3CA mutation: combination of alpelisib plus fulvestrant in real clinical practice by Filonenko, D. A., Ibragimova, T. M., Polshina, N. I., Belogurova, A. V., Khatkova, E. I., Arutiunian, E. A., Volkova, E. I., Zhukova, L. G.

“…Introduction . Сombination of alpelisib plus fulvestrant is approved in patients with hormone receptor positive, HER2-negative, PIK3CA-mutated advanced breast…”
Get full text

Role of palbociclib in the treatment of hormone receptor-positive HER2-negative metastatic breast cancer. Generalizing results of randomized trials and real clinical practice by Zhukova, L. G., Khatkova, E. I., Feoklistova, P. S., Grechukhina, K. S., Smolin, S. A., Arutyunyan, E. A., Kolyago, E. M.

“…Palbociclib is the first-in-class drug of CDK 4/6 inhibitors group. The use of palbociclib in combination with endocrinotherapy (ET) opens up new possibilities…”
Get full text

Optimal duration of adjuvant trastuzumab therapy in patients with HER2-possitive early breast cancer: whether the problem is resolved? by Zhukova, L G, Ganshina, I P, Khatkova, E I, Tikhomirova, T E, Kondratyeva, O E

“…According to the results of the conducted studies in the early 2000’s, adjuvant trastuzumab for 1 year has been admitted the gold standard since 2006. However,…”
Get full text

The use of regorafenib in patients with disseminated gastrointestinal stromal tumours. A review of the literature. A clinical case by D. A. Filonenko, S. V. Petukhova, E. I. Khatkova, K. A. Vorontsova, E. I. Chichikov, B. M. Medvedeva, L. G. Zhukova

“…The survival of patients even with disseminated disease reached 7–8 years after introduction of imatinib and sunitinib for the treatment of gastrointestinal…”
Get full text